期刊
LUNG CANCER
卷 69, 期 3, 页码 337-340出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2009.11.019
关键词
Lung cancer; Erlotinib; Bevacizumab; Serum biomarker; Proteomics; Personalized therapy
资金
- Vanderbilt Lung Cancer [P50 CA-90949, UO1 CA114771]
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat (R)) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat (R) could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据